Cargando…
Alteration of the Nucleotide Excision Repair (NER) Pathway in Soft Tissue Sarcoma
Clinical responses to anticancer therapies in advanced soft tissue sarcoma (STS) are unluckily restricted to a small subgroup of patients. Much of the inter-individual variability in treatment efficacy is as result of polymorphisms in genes encoding proteins involved in drug pharmacokinetics and pha...
Autores principales: | Pasqui, Adriano, Boddi, Anna, Campanacci, Domenico Andrea, Scoccianti, Guido, Bernini, Andrea, Grasso, Daniela, Gambale, Elisabetta, Scolari, Federico, Palchetti, Ilaria, Palomba, Annarita, Fancelli, Sara, Caliman, Enrico, Antonuzzo, Lorenzo, Pillozzi, Serena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369086/ https://www.ncbi.nlm.nih.gov/pubmed/35955506 http://dx.doi.org/10.3390/ijms23158360 |
Ejemplares similares
-
Soft Tissue Sarcoma: An Insight on Biomarkers at Molecular, Metabolic and Cellular Level
por: Pillozzi, Serena, et al.
Publicado: (2021) -
Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment
por: Gambale, Elisabetta, et al.
Publicado: (2022) -
Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study
por: Paderi, Agnese, et al.
Publicado: (2021) -
Nucleotide excision repair (NER) alterations as evolving biomarkers and therapeutic targets in epithelial cancers
por: Mouw, Kent W., et al.
Publicado: (2015) -
Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives
por: Fancelli, Sara, et al.
Publicado: (2021)